📰 Planegg News
Page 33 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year
October 21, 2022
MorphoSys AG / Key word(s): Change in ForecastAd hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 202221-Oct-2022 / 11:39 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQ...
October 21, 2022
EQS-News: MorphoSys AG / Key word: Change in Forecast MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 21.10.2022 / 11:41... | October 21, 2022
October 21, 2022
21.10.2022 - EQS-Ad-hoc: MorphoSys AG / Key word(s): Change in Forecast Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 21-Oct-2022 / 11:39 CET/CEST Disclosure of an inside information acc. to Article ... Seite 1
October 21, 2022
EQS-News: MorphoSys AG / Key word(s): Change in Forecast MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financi...
September 30, 2022
Significance Statement Membranous nephropathy (MN) is an autoimmune disease caused by circulating
September 29, 2022
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS...
September 29, 2022
BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided... | September 29, 2022
September 28, 2022
The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth Annual Meet
September 1, 2022
DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2...